The fractures that continue to weaken the foundation for currently marketed postmenopausal osteoporosis drugs offer a foothold to sponsors of new bone-building or bone-strengthening agents – but they’ll need to provide data sufficiently compelling to win over insurers who already have a wide choice of low-cost generic options.
Major Phase III programs are underway for new mechanisms to treat osteoporosis, including the partnership of Amgen Inc. and UCB Group, as well as Merck & Co. Inc., even though postmenopausal osteoporosis is considered a forbidding market to enter thanks to the wide range of generic drug therapies on offer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?